Summary of metabolic inhibitors currently in clinical trials
| Drug . | Pathway/target . | Trials (National Institutes of Health unless stated otherwise) . |
|---|---|---|
| 2-Deoxyglucose | Glycolysis | 2-Deoxyglucose: 249 trials (majority are for positron emission tomography) lonidamine |
| IACS-010759, IM156, and CPI-613 | TCA/ETC | IACS-010759: 2 trials, IM156: 30 trials, and CPI-613: 30 trials |
| Mildronate, trimetazidine, perhexiline, and etomoxir | Fatty acid oxidation | Mildronate: 2 trials; trimetazidine: 28 trials, perhexiline: 10 trials, etomoxir: preclinical |
| BCT-100, AEB1102, and ADI-PEG20 | Arginine metabolism | BCT-100: 9 trials, ADI-PEG20: 28 trials, and AEB1102: 3 trials |
| CB-839 (telaglenastat) and IPN60090 | Glutamine metabolism | CB-839: 22 trials and IPN60090: 2 trials |
| Sulfasalazine, cysteinase, and erastin | Cysteine metabolism | Sulfasalazine: used to treat rheumatoid arthritis, ulcerative colitis, and Crohn disease, 114 trials; cysteinase: preclinical; and erastin: preclinical |
| Asparaginase: Erwinase or Oncaspar | Asparagine metabolism | Used to treat ALL: 296 trials |
| Methotrexate and SHIN1/2 | Serine metabolism | Methotrexate: used to treat multiple cancer types and autoimmune disease, 2300 trials and SHIN1/2: preclinical |
| ERG-240 | BCAA metabolism | Preclinical |
| JPH203 | LAT1 | UMIN000016546 |
| Drug . | Pathway/target . | Trials (National Institutes of Health unless stated otherwise) . |
|---|---|---|
| 2-Deoxyglucose | Glycolysis | 2-Deoxyglucose: 249 trials (majority are for positron emission tomography) lonidamine |
| IACS-010759, IM156, and CPI-613 | TCA/ETC | IACS-010759: 2 trials, IM156: 30 trials, and CPI-613: 30 trials |
| Mildronate, trimetazidine, perhexiline, and etomoxir | Fatty acid oxidation | Mildronate: 2 trials; trimetazidine: 28 trials, perhexiline: 10 trials, etomoxir: preclinical |
| BCT-100, AEB1102, and ADI-PEG20 | Arginine metabolism | BCT-100: 9 trials, ADI-PEG20: 28 trials, and AEB1102: 3 trials |
| CB-839 (telaglenastat) and IPN60090 | Glutamine metabolism | CB-839: 22 trials and IPN60090: 2 trials |
| Sulfasalazine, cysteinase, and erastin | Cysteine metabolism | Sulfasalazine: used to treat rheumatoid arthritis, ulcerative colitis, and Crohn disease, 114 trials; cysteinase: preclinical; and erastin: preclinical |
| Asparaginase: Erwinase or Oncaspar | Asparagine metabolism | Used to treat ALL: 296 trials |
| Methotrexate and SHIN1/2 | Serine metabolism | Methotrexate: used to treat multiple cancer types and autoimmune disease, 2300 trials and SHIN1/2: preclinical |
| ERG-240 | BCAA metabolism | Preclinical |
| JPH203 | LAT1 | UMIN000016546 |